FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: fda

Sort
E.g., 2013-05-18
E.g., 2013-05-18
Enter a comma separated list of user names.

The Food and Drug Administration has approved Arena Pharmaceutical's anti-obesity pill Belviq, the first new prescription drug for long-term weight loss to enter the U.S. market in over a decade.

Despite only achieving modest weight loss in clinical studies, the drug appeared safe enough to win the FDA's endorsement, amid calls from doctors for new weight-loss treatments.

The agency cleared the pill Wednesday for adults who are obese or are overweight with at least one medical complication, such as diabetes or high cholesterol.

AMRN, Amarin Corporation plc

** AMRN reported that its New Drug Application for AMR101 has been accepted for filing by the FDA

AMRN is developing AMR101 for the treatment of patients with very high triglyceride levels and as a potentially first-in-class therapy for patients with high triglyceride levels who are also on statin therapy for elevated LDL-cholesterol levels.

Shares in Amarin Corporation recently fell 10%, due to a decision by the US Patent and Trademark Office to issue a non-final rejection of a patent linked to AMR101, a lipid reduction drug that helps to treat high levels of triglycerides in patients.

** Amazon.com Inc. (AMZN) reported its operating cash flow increased 25% to $3.21 billion for the trailing twelve months and net sales increased 51% to $9.91 billion in the second quarter 2011 compared to the same period the prior year.

****************************

Ballard Power Systems Inc. (BLDP) reported a purchase order commitment from Plug Power Inc. for a minimum 3,250 fuel cell stacks over the next 18-month period, for use in the material handling market.

*********************************

Now settled-in to their new state-of-the-art facilities, Unilife has hit another milestone with the commencement of shipments of the Unifill syringe to Sanofi. This article discusses the next phase of the Unilife/Sanofi contract as well as features Alan Shortall, CEO of Unilife, in a brief video showing the proprietary syringe.

Article except:

Industry leaders, such as former FDA Chief David Kessler add a great deal of credibility to the products that are being developed by 22nd Century Group. Kessler, along with people such as Harvard professor Greg Connolly have publicly commented on the FDA not exercising their authority to mandate lower levels of nicotine in cigarettes.

Article excerpt:

Bruker Corporation (NASDAQ:BRKR) will present at the Deutsche Bank 36th Annual Healthcare Conference on Monday, May 2nd, 2011, at 10 a.m. Eastern Daylight Time at the InterContinental Boston. A live audio webcast of this presentation will be available on the Investor section of the Company's Web site at http://ir.bruker.com

Pages

ADVERTISE WITH US